EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access

Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B

Ulrike M Reiss iD, Andrew M Davidoff, Edward G D Tuddenham, Pratima Chowdary, Jenny McIntosh, Vincent Muczynski, Malo Journou, Giulia Simini, Lydia Ireland, Saira Mohamed, Anne Riddell, Arnulfo J Pie und 16 weitere

New England Journal of Medicine · 12.06.2025 · 392 (22) · 2226-2234

DOI: 10.1056/nejmoa2414783 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 12.06.2025. Verfasst von Ulrike M Reiss und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN. Hauptthemen laut MEDLINE: Dependovirus, Factor IX, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Department of Health, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusFactor IXGenetic TherapyGenetic VectorsHemophilia BAdultHumansMaleMiddle AgedYoung AdultBlood Coagulation FactorsFollow-Up StudiesHemorrhageInfusions, IntravenousSeverity of Illness IndexTreatment OutcomeLongitudinal Studies

Substanzen

Blood Coagulation FactorsFactor IXprothrombin complex concentrates

Autor:innen und Institutionen

  • Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
  • Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN.
  • Katharine Dormandy Haemophilia and Thrombosis Unit, Royal Free Hospital, London.
  • Cancer Institute, University College London, London.
  • Sheila Sherlock Liver Centre, Royal Free Hospital, London.
  • Basingstoke and North Hampshire Hospital NHS Foundation Trust, Basingstoke, United Kingdom.

ORCID-Profile: Ulrike M Reiss, Johnny Mahlangu

Förderung

  • NIH HHS
  • Department of Health
  • Medical Research Council
  • NHLBI NIH HHS
  • Horizon 2020
  • NIHR
  • NIH
  • EU Horizon 2020

Zitieren

APA

Reiss, U. M., Davidoff, A. M., Tuddenham, E. G. D., Chowdary, P., McIntosh, J., Muczynski, V., Journou, M., Simini, G., Ireland, L., Mohamed, S., Riddell, A., Pie, A. J., Hall, A., Quaglia, A., Mangles, S., Mahlangu, J., Haley, K., Recht, M., Shen, Y. M., …, & Nathwani, A. C. (2025). Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B. New England Journal of Medicine, 392(22), 2226-2234. https://doi.org/10.1056/nejmoa2414783

Vancouver

Reiss UM, Davidoff AM, Tuddenham EGD, Chowdary P, McIntosh J, Muczynski V, et al. Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B. New England Journal of Medicine. 2025;392(22):2226-2234. doi:10.1056/nejmoa2414783

BibTeX
@article{Reiss2025,
  author = {Reiss, Ulrike M and Davidoff, Andrew M and Tuddenham, Edward G D and Chowdary, Pratima and McIntosh, Jenny and Muczynski, Vincent and Journou, Malo and Simini, Giulia and Ireland, Lydia and Mohamed, Saira and Riddell, Anne and Pie, Arnulfo J and Hall, Andrew and Quaglia, Alberto and Mangles, Sarah and Mahlangu, Johnny and Haley, Kristina and Recht, Michael and Shen, Yu-Min and Halka, Kathleen G and Fortner, Gail and Morton, Christopher L and Gu, Zhengming and Hayden, Randall T and Neufeld, Ellis J and Okhomina, Victoria I and Kang, Guolian and Nathwani, Amit C},
  title = {Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {22},
  pages = {2226--2234},
  doi = {10.1056/nejmoa2414783}
}
Kostenlos starten →